10x (TXG) Forward Price-to-Revenue Multiple

Public company logo of 10x Genomics, Inc. (TXG)

Under the leadership of Serge Sakhsonov, 10x Genomics, Inc. (TXG) strives for leadership in single-cell analysis through patent protection. The organization's forward P/S visualizes market volatility, where 11.60 determines the latest valuation metric. Revenue is based on sales of consumables and Chromium instruments, although management is currently facing a slowdown in equipment sales rates.

10x Genomics - TXG Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/13/2026)

Summary analytical data breakdowns for 10x (TXG)

- market price and analyst price targets:
Price Chart 10x Genomics|TXG - Analyst Median Target
- market capitalization details:
Market Valuation 10x|TXG - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share 10x Genomics|TXG - Book Valuation of Business|Market Value to Book Value Ratio 10xgenomics.com|TXG - Total Business Assets
- debt and solvency information:
Total Debt to Capital 10x Genomics, Inc.|TXG - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio 10x Genomics, Inc.|TXG - Company Total Debt Obligations|Debt to Book Value 10x|TXG - Amount of Long-Term Liabilities|Company Current Liabilities 10x Genomics|Quick Ratio 10xgenomics.com
- financial results and valuation multiples details:
TXG - Annual Net Income|Projected Future Earnings 10x Genomics, Inc.|TXG - Price to Earnings Multiple|Future Price to Earnings 10x Genomics Corp|TXG - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple 10x|TXG - Operating profit EBITDA|Net earnings per share (EPS TTM) 10x Genomics|TXG - Earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months 10xgenomics.com|TXG - Earnings per share growth this year|Expected earnings per share growth for next year 10x Genomics, Inc.
- sales volume and revenue indicators:
TXG - Company Sales Revenue|Projected Sales Volume 10x Genomics|TXG - Price-to-Revenue Multiple|Forward P/S Multiple 10x
Comprehensive company analysis:10x Genomics (TXG)
Product sample of 10xgenomics.com

The investment attractiveness of 10x Genomics, Inc. (TXG) depends on the company's ability to maintain its leadership in spatial biology amid intensifying competition and patent wars. This metric assesses the current share price relative to expected revenue, measuring market optimism regarding future sales. Sharp fluctuations in the forward price-to-sales ratio signal a revision of confidence in growth forecasts during periods of external shocks. Analyzing the amplitude of this chart helps determine the balance between speculative undervaluation and the risk of long-term capital depreciation.

Competing companies

Price-to-Projected Revenue Ratio Tempus AI, Inc. TEM|Market Cap to Expected Sales Ratio Qiagen NV (QGEN)|IONS: Forward Price-to-Revenue Multiple|Forward Price to Sales RGEN (Repligen Inc.)|RNA: Forward P/S Multiple|CRSP - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio GeneDx|Market Cap to Projected Revenue RARE (Ultragenyx Pharmaceutical Inc.)|Forward P/S Multiple BEAM|Forward Price-to-Revenue Multiple Sarepta Corp SRPT|Twist Bioscience - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio intelliatx.com (NTLA)|STOK: Forward Price-to-Revenue Multiple|BioLife Solutions Inc - Price to Expected Revenue Ratio|WVE (Wave Life Sciences Corp) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue MAZE|SION (Sionna Therapeutics Inc) - Forward P/S Multiple|PRME - Projected Price to Revenue|Forward P/S Multiple TSHA|uniQure NV - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio MeiraGTx PLC MGTX|RGNX: Market Cap to Projected Revenue|Solid Biosciences Inc. - Forward P/S Multiple|OCGN - Forward P/S Multiple|PACB: Forward P/S Multiple|BNTC: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple DSGN|Market Cap to Projected Revenue RCKT (Rocket Corp)|Forward Price-to-Revenue Multiple FDMT (4D Molecular Therapeutics)|LXEO (lexeotx.com) - Forward Price to Sales|Forward P/S Multiple KRRO (Korro Bio)|Projected Price to Revenue Editas Medicine Inc|Silence Therapeutics Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio ProQR Therapeutics N.V.|codexis.com (CDXS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue SGMO|Price-to-Projected Revenue Ratio Nautilus Biotechnology, Inc.|Market Cap to Future Revenue Ratio Metagenomi Inc. MGX|Price-to-Projected Revenue Ratio Precision BioSciences, Inc. (DTIL)|Forward Price-to-Revenue Multiple generationbio.com GBIO|Forward P/S Multiple BOLD (Boundless Bio, Inc.)|Market Cap to Expected Sales Ratio Exicure Inc. (XCUR)|Celsion Corporation - Forward P/S Multiple|Phio Pharmaceuticals (PHIO) - Forward Price-to-Revenue Multiple|mustangbio.com (MBIO) - Price-to-Projected Revenue Ratio|RNAZ - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple BNGO|APDN: Forward Price to Sales|Forward P/S Multiple BLUE|Market Cap to Expected Sales Ratio immunoprecise.com|Price-to-Projected Revenue Ratio Omega OMGA|OMIC: Market Cap to Projected Revenue|Regulus Therapeutics - Forward P/S Multiple|syros.com (SYRS) - Forward Price-to-Revenue Multiple|TBIO (Telesis Bio) - Forward Price-to-Revenue Multiple|TCON - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple UBX